PROMEDIOR

Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, an... d greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.
PROMEDIOR
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.promedior.com
Total Employee:
51+
Status:
Active
Contact:
781-538-4200
Email Addresses:
[email protected]
Total Funding:
63 M USD
Technology used in webpage:
Viewport Meta Domain Not Resolving SPF Google Maps Mobile Non Scaleable Content IPv6 Microsoft Mimecast Akamai DNS
Similar Organizations
Acologix
Acologix is a biopharmaceutical company developing therapeutic compounds for the treatment of osteo-renal diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Baergic Bio
Baergic Bio is a biopharmaceutical company that develops and commercialises novel therapeutics for the treatment of CNS disorders.
Complexa
Complexa, a biopharmaceutical company, develops therapies for the treatment of inflammatory, and metabolic diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
ReVision Therapeutics
ReVision Therapeutics, a biopharmaceutical company, develops drugs for the treatment of age-related macular degeneration diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Promedior
Shire
Shire investment in Series D - Promedior
HealthCare Ventures
HealthCare Ventures investment in Series D - Promedior
Forbion Capital Partners
Forbion Capital Partners investment in Series D - Promedior
Fibrotic Ventures
Fibrotic Ventures investment in Series D - Promedior
Polaris Partners
Polaris Partners investment in Series D - Promedior
Morgenthaler Ventures
Morgenthaler Ventures investment in Series D - Promedior
Easton Capital
Easton Capital investment in Series D - Promedior
Easton Capital
Easton Capital investment in Series D - Promedior
Fibrotic Ventures
Fibrotic Ventures investment in Series D - Promedior
Official Site Inspections
http://www.promedior.com
- Host name: heps.roche.com
- IP address: 198.21.19.135
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Promedior"
Promedior Company Profile 2024: Valuation, Investors ... - PitchBook
Promedior General Information Description. Developer of therapeutics designed to treat fibrotic diseases. The company is focused on rare fibrotic diseases including idiopathic pulmonary โฆSee details»
Promedior, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Promedior, Inc. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
Promedior | VentureRadar
Website: http://www.promedior.com/ Develops targeted therapeutics for fibrosis treatment using proprietary platform based on Pentraxin-2, aiming to prevent and ...See details»
Promedior Inc - Company Profile and News - Bloomberg Markets
Promedior, Inc. manufactures pharmaceutical products. The Company develops therapeutics for a wide variety of serious fibrotic diseases of the lung, kidney, and eye, as well as pulmonary โฆSee details»
Promedior - Company Profile - Tracxn
Nov 25, 2024 Promedior is a clinical-stage biotechnology company that develops targeted therapeutics to treat diseases involving fibrosis. Promedior's proprietary platform is based โฆSee details»
Promedior - Company profile | ensun
Health Care, Other Investment Pools and Funds, Manufacturing, Other Financial Investment Activities, Management investment, open-end, Sugar and Confectionery Product โฆSee details»
Roche acquires Promedior - 2019-11-15 - Crunchbase
Nov 15, 2019 Acquired Organization: Promedior Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases. โฆSee details»
Promedior - Tech Company Profile - Gaebler.com Venture Capital โฆ
Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic disorders and diseases.See details»
Promedior, Inc. Company Profile: Financials, Valuation, and Growth
Promedior, Inc. is a pharmaceutical development and manufacturing company. Promedior, Inc. was founded in 2006 by Jim Broderick. Promedior, Inc. headquarters are located in Malvern, โฆSee details»
Promedior, Inc.:Company Profile & Technical Research,Competitor โฆ
Promedior, Inc. is a company that provides Pharmacy and Therapeutics, Medicine, Pulmonary fibrosis and more. Promedior, Inc. is headquartered in United States Massachusetts.See details»
Promedior - EquityNet
Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug โฆSee details»
Promedior - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
Promedior - Crunchbase
Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases.See details»
Promedior IPO - Linqto
Promedior, founded in 2006 and headquartered in Lexington, Massachusetts, is a clinical-stage immunotherapy company focused on developing targeted therapeutics for fibrosis-related โฆSee details»
Promedior Enters Into Definitive Merger Agreement To Be โฆ
LEXINGTON, Mass., Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to โฆSee details»
Promedior - Founders and Board of Directors - Tracxn
Nov 17, 2024 Promedior's founder is Jim Broderick. Promedior founders & board of directors. Targeted protein-based therapeutics to treat fibrotic diseases such as Idiopathic Pulmonary โฆSee details»
Promedior - Contacts, Employees, Board Members, Advisors
Organization. Promedior . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of Board โฆSee details»
Promediol SA Company Profile | Montagnola, TICINO, Switzerland ...
Find company research, competitor information, contact details & financial data for Promediol SA of Montagnola, TICINO. Get the latest business insights from Dun & Bradstreet.See details»
Promediol โ Swiss Therapeutic Solutions
Promediol SA is a Swiss company focused on health and quality of life. Our headquarter is located in canton Ticino, in the heart of Switzerland and Europe, just a few hours from France, โฆSee details»
Promedior - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases.See details»